Filing Flows › NovoCure (NVCR) › Q2 2026
NovoCure (NVCR) Q2 2026 earnings results (second quarter 2026)
10-Q filed Jul 23, 2026
NovoCure (NVCR) reported revenue of $184M for the second quarter 2026 (Q2 2026), +16% from a year earlier and +5% from the quarter before. Operating margin was -5.8%, net loss $15.7M (8.5% of revenue).
NovoCure, Q2 2026: revenue $184M (+16% year over year), operating margin -5.8%, net loss $15.7M, operating cash flow $8.1M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $184M | +5% | +16% |
| Operating profit | −$10.6M | — | — |
| Net earnings | −$15.7M | — | — |
| Operating cash flow | $8.1M | — | — |
| Free cash flow | $1.2M | — | — |
What changed
Revenue was $183.6M in Q2 2026, up 16% year over year and up 5% from the previous quarter.
Gross margin was 77.6%, up 3.7 points from Q2 2025. Operating costs exceeded revenue by $10.6M, an operating margin of -5.8%. Operating expenses fell 2% while revenue rose 16%. The quarter ended with a net loss of $15.7M, narrower than the previous quarter's $71.1M loss.
Operating cash flow was $8.1M. Non-cash charges added back $4.3M of depreciation and amortization and $17.0M of share-based compensation. Working capital and other items added $2.5M. Capital expenditures of $6.9M left free cash flow of $1.2M.
Questions
What was NovoCure's revenue in the second quarter 2026?
NovoCure (NVCR) reported revenue of $184M for the second quarter 2026 (Q2 2026), +16% from a year earlier and +5% from the quarter before.
Was NovoCure profitable in the second quarter 2026?
Operating loss was $10.6M (-5.8% of revenue) and net loss $15.7M.
Source: NovoCure 10-Q on SEC EDGAR.